Historical Valuation
SINO BIOPHARM (01177) is now in the Fair zone, suggesting that its current forward PE ratio of 22.90 is considered Fairly compared with the five-year average of 20.18. The fair price of SINO BIOPHARM (01177) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：7.00
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
SINO BIOPHARM (01177) has a current Price-to-Book (P/B) ratio of 3.13. Compared to its 3-year average P/B ratio of 2.15 , the current P/B ratio is approximately 45.35% higher. Relative to its 5-year average P/B ratio of 2.81, the current P/B ratio is about 11.47% higher. SINO BIOPHARM (01177) has a Forward Free Cash Flow (FCF) yield of approximately 5.76%. Compared to its 3-year average FCF yield of 7.98%, the current FCF yield is approximately -27.86% lower. Relative to its 5-year average FCF yield of 6.15% , the current FCF yield is about -6.46% lower.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of 01177 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of 01177 in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is 01177 currently overvalued or undervalued?
SINO BIOPHARM (01177) is now in the Fair zone, suggesting that its current forward PE ratio of 22.90 is considered Fairly compared with the five-year average of 20.18. The fair price of SINO BIOPHARM (01177) is between to according to relative valuation methord.
What is SINO BIOPHARM (01177) fair value?
01177's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of SINO BIOPHARM (01177) is between to according to relative valuation methord.
How does 01177's valuation metrics compare to the industry average?
The average P/S ratio for 01177's competitors is , providing a benchmark for relative valuation. SINO BIOPHARM Corp (01177) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for SINO BIOPHARM (01177) as of Jan 15 2026?
As of Jan 15 2026, SINO BIOPHARM (01177) has a P/B ratio of 3.13. This indicates that the market values 01177 at 3.13 times its book value.
What is the current FCF Yield for SINO BIOPHARM (01177) as of Jan 15 2026?
As of Jan 15 2026, SINO BIOPHARM (01177) has a FCF Yield of 5.76%. This means that for every dollar of SINO BIOPHARM’s market capitalization, the company generates 5.76 cents in free cash flow.
What is the current Forward P/E ratio for SINO BIOPHARM (01177) as of Jan 15 2026?
As of Jan 15 2026, SINO BIOPHARM (01177) has a Forward P/E ratio of 22.90. This means the market is willing to pay $22.90 for every dollar of SINO BIOPHARM’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for SINO BIOPHARM (01177) as of Jan 15 2026?
As of Jan 15 2026, SINO BIOPHARM (01177) has a Forward P/S ratio of 2.95. This means the market is valuing 01177 at $2.95 for every dollar of expected revenue over the next 12 months.